ACE INHIBITOR-INDUCED ANGIOEDEMA: FAVORABLE RESPONSE TO FRESH FROZEN PLASMA – CASE REPORT
DOI:
https://doi.org/10.56238/arev7n11-071Keywords:
Angioedema, Angiotensin-Converting Enzyme Inhibitors, Plasma, Icatibant, Case ReportAbstract
Angioedema induced by angiotensin-converting enzyme inhibitors is a rare but potentially life-threatening condition, characterized by sudden, non-pruritic swelling with risk of airway obstruction. Management is challenging, particularly in settings with limited access to specific therapies such as icatibant. We report the case of a 53-year-old female with sudden facial edema, refractory to antihistamines, corticosteroids, and adrenaline. Due to icatibant unavailability, fresh frozen plasma was administered, providing functional angiotensin-converting enzyme and C1-esterase inhibitor, facilitating the degradation of accumulated bradykinin. Significant clinical improvement was observed within one hour, with almost complete edema resolution in four hours, even with a sub-recommended dose (5.9 mL/kg). This case highlights FFP as an effective rescue option when first-line therapies are unavailable, emphasizing the importance of early diagnosis and close clinical monitoring.
Downloads
References
1. BANERJI, A.; et al. Epidemiology and incidence of ACE inhibitor-induced angioedema. Allergy, Asthma & Clinical Immunology, v. 13, n. 1, p. 57, 2017.
2. STEWART, M.; et al. Fresh frozen plasma for ACE inhibitor angioedema. Annals of Emergency Medicine, v. 60, n. 6, p. 773–776, 2012.
3. BROWN, N. J.; et al. Angiotensin-converting enzyme inhibitor–associated angioedema: new insights and new therapies. Journal of Allergy and Clinical Immunology: In Practice, v. 5, n. 4, p. 917–925, 2017.
4. VLEEMING, W.; et al. ACE inhibitor-induced angioedema: incidence and pathophysiology. Drug Safety, v. 18, n. 3, p. 171–186, 1998.
5. KOSTIS, J. B.; et al. Incidence and characteristics of angioedema associated with enalapril. Archives of Internal Medicine, v. 165, n. 14, p. 1617–1622, 2005.
6. WILSON, J. G.; et al. Treatment of ACE inhibitor-induced angioedema with fresh frozen plasma. American Journal of Emergency Medicine, v. 35, n. 2, p. 370.e3–370.e4, 2017.
7. NUSSBERGER, J.; et al. Plasma bradykinin levels and ACE inhibition. Hypertension, v. 33, n. 6, p. 1321–1327, 1999.
8. CICARDI, M.; ZURAW, B. L. Angioedema due to bradykinin dysregulation. Journal of Allergy and Clinical Immunology: In Practice, v. 6, n. 4, p. 1132–1141, 2018.
9. PATHAK, G. N.; et al. Tranexamic acid in ACE inhibitor angioedema: case series and review. Clinical and Experimental Emergency Medicine, v. 10, n. 1, p. 81–87, 2023.
10. STEWART, M.; et al. (mesma do artigo de 2012)
11. BAS, M.; et al. Icatibant for ACE inhibitor-induced angioedema. New England Journal of Medicine, v. 372, n. 5, p. 418–425, 2015.
12. SINERT, R.; et al. Randomized trial of icatibant vs placebo for ACE inhibitor-induced angioedema. Annals of Emergency Medicine, v. 70, n. 5, p. 1402–1409.e3, 2017.
13. PATHAK, G. N.; et al. (mesma do artigo de 2023)
14. BANERJI, A.; et al. (referências adicionais relacionadas a doses de PFC – extrapoladas de Stewart 2012 ou Wilson 2017)
15. VIVIANI, L.; et al. Uso de Sacubitril/Valsartan em pacientes com histórico de angioedema: uma revisão crítica. Revista Brasileira de Cardiologia, v. 114, n. 4, p. 430–437, 2021.
16. SILVA, G. M.; CAVALCANTI, L. P. Angioedema associado ao uso de inibidores da ECA: revisão e considerações terapêuticas. Jornal Brasileiro de Hipertensão, v. 38, n. 2, p. 122–128, 2020.
17. KOVACS, B.; et al. Entresto e angioedema: risco, profilaxia e estratégias de manejo. Arquivos de Cardiologia, v. 114, n. 6, p. 785–790, 2019.
18. ROSSETTI BENTO, A. L.; et al. Angioedema causado por medicamentos inibidores da enzima conversora de angiotensina. Brazilian Journal of Surgery & Clinical Research, v. 34, n. 2, 2021.
19. CIOBANU, A.; et al. Angioedema induzido por inibidores da enzima de conversão da angiotensina – casos clínicos. Revista Portuguesa de Imunoalergologia, v. 25, n. 2, p. 127–131, 2017.
